Search results
Results from the WOW.Com Content Network
Here's what lies ahead for Hims & Hers Health stock In the short term, management previously guided for its fourth-quarter 2024 revenue to be within the range of $465 million to $470 million.
Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Entering trading this week, the stock has fallen by around 15% in value in the past ...
Trading at a forward price-to-earnings (P/E) ratio of under 21 times next year's analyst estimates, Hims & Hers' stock is very attractively priced for a company with its revenue growth and gross ...
The GLP-1 hype has left the stock. Hims & Hers is a consumer-facing telehealth company that offers medical consultations and prescribes medications and other products for various health-related ...
The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of July 15, 2024. Will Ebiefung has positions in Hims & Hers ...
Growth is set to accelerate starting next quarter, powered by its GLP-1 offering.
Price Action: HIMS stock is up 5.77% at $28.23 at the last check Wednesday. Read Next: Boeing Forecasts 67% Growth In Global Air Cargo Fleet By 2043, Driven By Asia Demand.
For premium support please call: 800-290-4726 more ways to reach us